Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT04890093
- Locations
- 🇺🇸
Childrens National Medical Center, Washington, District of Columbia, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
AGuIX Nanoparticles with Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Centre Jean Perrin
- Target Recruit Count
- 66
- Registration Number
- NCT04881032
- Locations
- 🇫🇷
CHU de Brest, Brest, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷CHU de Grenoble, Grenoble, France
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Xennials Therapeutics Australia Pty Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT04851834
- Locations
- 🇦🇺
St. George Private Hospital, Kogarah, New South Wales, Australia
🇦🇺St. Vincent's Hospital - The Kinghorn Cancer Center, Darlinghurst, New South Wales, Australia
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 73
- Registration Number
- NCT04817254
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
- Conditions
- Interventions
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT04796012
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 62
- Registration Number
- NCT04743661
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04737889
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2022-04-04
- Target Recruit Count
- 18
- Registration Number
- NCT04689347
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2020-12-19
- Target Recruit Count
- 30
- Registration Number
- NCT04674527
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.